Document:

EX-10.5

 EXHIBIT 10.5 

AEGLEA BIOTHERAPEUTICS, INC. 

STOCK RESTRICTION AGREEMENT 

This Stock Restriction Agreement (this “Agreement”) is made and entered into as of March 10, 2015 (the
“Effective Date”) by and between Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), and
                 (“Stockholder”). 

R E C I T A L S 

A. Stockholder was the owner of                 
Common B Shares (the “Units”) of Aeglea BioTherapeutics Holdings, LLC, the predecessor in interest of the Company (the “Predecessor LLC”), acquired pursuant to that certain Award Agreement dated as of
                     by and between the Stockholder and the Predecessor LLC (the “Award Agreement”).  

B. Pursuant to that certain Plan of Conversion, dated as of the date hereof, the Units converted into
                 shares (the “Shares”) of the Company’s Common Stock (such conversion of the Units into Shares, the
“Conversion”), and as of such date     % of the Units were vested and     % of the Units were unvested in accordance with the terms of the Award Agreement. 

C. To induce certain investors to purchase shares of the Company’s Series B Preferred Stock pursuant to that certain Series B Preferred
Stock Purchase Agreement by and among the Company and such investors dated of even date herewith, and as an incentive for Stockholder to remain with the Company or an Affiliate (as defined below) of the Company, the parties have agreed upon a
mechanism for the repurchase of certain of the Shares from Stockholder should Stockholder’s relationship with the Company terminate, all as more fully set forth below. 

NOW, THEREFORE, in consideration of the mutual promises herein contained, the Company and Stockholder agree as follows. 

1. MARKET STANDOFF AGREEMENT. Stockholder hereby agrees that during a period, not to exceed 180 days (or, if required by such
underwriter, such longer period of time as is necessary to enable such underwriter to issue a research report or make a public appearance that relates to an earnings release or announcement by the Company within 18 days prior to or after the date
that is one hundred eighty (180) days after the effective date of the registration statement relating to such offering, but in any event not to exceed two hundred ten (210) days following the effective date of the registration statement
relating to such offering), following the effective date of the initial, effective registration statement of the Company filed under the Securities Act (“IPO”), it shall not, to the extent requested by the Company and any
underwriter, sell, pledge, transfer, make any short sale of, loan, grant any option for the purchase of, or otherwise transfer or dispose of any Capital Stock of the Company held by it at any time during such period except Capital Stock included in
such registration. The underwriters in connection with the IPO are intended third-party beneficiaries of this Section 1 and shall have the right, 

  
 1 

 
power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters
in the IPO that are consistent with this Section 1 or that are necessary to give further effect thereto. 
 2. RESTRICTIONS ON
TRANSFER. Stockholder acknowledges and agrees that neither Unvested Shares (defined below) nor Vested Shares (defined below) may be sold or otherwise transferred in any manner otherwise than by will or by the laws of descent or distribution,
without the prior written consent of the Company. The terms of this Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of Stockholder. The restrictions on transfer set forth in this Section 2 will
expire on the earlier of an IPO or a Company Sale (as defined in the Company’s restated certificate of incorporation, as may be amended from time to time). 

3. SUPPLEMENTAL RIGHT OF FIRST REFUSAL. In addition to the restrictions on transfer set forth in Section 2 above, and any
restrictions on transfer applicable under the that certain Right of First Refusal and Co-Sale Agreement dated March 9, 2015 between the Company and certain investors and other stockholders, as may be amended from time to time, Stockholder
acknowledges and agrees that if the foregoing restrictions are not applicable for any reason, then the following restrictions on transfer shall instead apply: (i) Unvested Shares (defined below) may not be sold or otherwise transferred by
Stockholder without the Company’s prior written consent, and (ii) that before any Vested Shares held by Stockholder or any transferee of such Vested Shares (either sometimes referred to herein as the “Holder”) may
be sold or otherwise transferred (including without limitation a transfer by gift or operation of law), the Company and/or its assignee(s) will have a right of first refusal to purchase the Shares to be sold or transferred (the “Offered
Shares”) on the terms and conditions set forth in this Section 3 (the “Right of First Refusal”). 

3.1. Notice of Proposed Transfer. The Holder of the Offered Shares will deliver to the Company a written notice (the
“Notice”) stating: (a) the Holder’s bona fide intention to sell or otherwise transfer the Offered Shares; (b) the name and address of each proposed purchaser or other transferee (the “Proposed
Transferee”); (c) the number of Offered Shares to be transferred to each Proposed Transferee; (d) the bona fide cash price or other consideration for which the Holder proposes to transfer the Offered Shares (the
“Offered Price”); and (e) that the Holder acknowledges this Notice is an offer to sell the Offered Shares to the Company and/or its assignee(s) pursuant to the Company’s Right of First Refusal at the Offered Price
as provided for in this Agreement. 
 3.2. Exercise of Right of First Refusal. At any time within thirty (30) days after
the date the Notice was effective in accordance with Section 10.1 hereof, the Company and/or its assignee(s) may, by giving written notice to the Holder, elect to purchase all (or, with the consent of the Holder, less than all) the Offered
Shares proposed to be transferred to any one or more of the Proposed Transferees named in the Notice, at the purchase price determined in accordance with Section 3.3 below. 

  
 2 

 3.3. Purchase Price. The purchase price for the Offered Shares purchased under this
Section will be the Offered Price, provided that if the Offered Price consists of no legal consideration (as, for example, in the case of a transfer by gift), the purchase price will be the fair market value of the Offered Shares as determined in
good faith by the Company’s Board of Directors. If the Offered Price includes consideration other than cash, then the value of the non-cash consideration, as determined in good faith by the Company’s Board of Directors, will conclusively
be deemed to be the cash equivalent value of such non-cash consideration. 
 3.4. Payment. Payment of the purchase price for
the Offered Shares will be payable, at the option of the Company and/or its assignee(s) (as applicable), by check or by cancellation of all or a portion of any outstanding indebtedness owed by the Holder to the Company (or to such assignee, in the
case of a purchase of Offered Shares by such assignee) or by any combination thereof. The purchase price will be paid without interest within sixty (60) days after the Company’s receipt of the Notice, or, at the option of the Company
and/or its assignee(s), in the manner and at the time(s) set forth in the Notice. 
 3.5. Exempt Transfers. Notwithstanding
anything to the contrary in this Section, the following transfers of Vested Shares will be exempt from the Right of First Refusal: (a) the transfer of any or all of the Vested Shares during Stockholder’s lifetime by gift or on
Stockholder’s death by will or intestacy to Stockholder’s “Immediate Family” (as defined below) or to a trust for the benefit of Stockholder or Stockholder’s Immediate Family, provided that each transferee or
other recipient agrees in a writing satisfactory to the Company that the provisions of this Section will continue to apply to the transferred Vested Shares in the hands of such transferee or other recipient; (b) except as provided in
Section 4.2.2 clause (b) below, any transfer or conversion of Vested Shares made pursuant to a statutory merger or statutory consolidation of the Company with or into another corporation or corporations; or (c) any transfer of Vested
Shares pursuant to the winding up and dissolution of the Company. As used herein, the term “Immediate Family” will mean Stockholder’s spouse, the lineal descendant or antecedent, brother or sister, of Stockholder or
Stockholder’s spouse, or the spouse of any lineal descendant or antecedent, brother or sister of Stockholder, or Stockholder’s spouse, whether or not any of the above are adopted. 

3.6. Termination of Right of First Refusal. The Right of First Refusal will terminate as to all Shares (a) on the effective
date of the first sale of Common Stock of the Company to the general public pursuant to a registration statement filed with and declared effective by the SEC under the 1933 Act (other than a registration statement relating solely to the issuance of
Common Stock pursuant to a business combination or an employee incentive or benefit plan) or (b) on any transfer or conversion of Shares made pursuant to a statutory merger or statutory consolidation of the Company with or into another
corporation or corporations if the common stock of the surviving corporation or any direct or indirect parent corporation thereof is registered under the Securities Exchange Act of 1934, as amended. 

4. COMPANY’S REPURCHASE OPTIONS. The Company and its assignees shall have the option, exercisable if Stockholder ceases to
be employed by the Company (as defined herein) for any reason, or no reason, including without limitation Stockholder’s death, disability, voluntary resignation or termination by the Company with or without cause, to (i) repurchase all or
a portion of the Unvested Shares then held by Stockholder on the terms and conditions set 

  
 3 

 
forth in Section 4.4 (the “Unvested Share Repurchase Option”) and (ii) repurchase all or a portion of the Vested Shares then held by Stockholder on the
terms and conditions set forth in Section 4.4 (the “Vested Share Repurchase Option”). 
 4.1.
Definition of “Employed by the Company”; “Termination Date”. For purposes of this Agreement, Stockholder will be considered to be “employed by the Company” if the Board of Directors of the
Company (the “Board”) determines that Stockholder is rendering substantial services as an officer, employee, consultant or independent contractor to the Company or to any Affiliate of the Company. In case of any dispute as to
whether Stockholder is employed by the Company, the Board shall have sole discretion to determine whether Stockholder has ceased to be employed by the Company or any Affiliate and the effective date on which Stockholder’s employment terminated
(the “Termination Date”). An “Affiliate” means any entity that owns, directly or indirectly, shares representing more than 50% of the total combined voting power of all classes of capital stock of the
Company or any entity in which the Company owns, directly or indirectly, equity interests representing more than 50% of the voting power of such entity. 

4.2. Unvested and Vested Shares. 

4.2.1 Vesting Schedule. [Example only] Shares that are vested pursuant to the schedule set forth herein are
“Vested Shares”. Shares that are not vested pursuant to the schedule set forth herein are “Unvested Shares”. On the Effective Date
[                    ] of the Shares will be Unvested Shares and
[                ] of the Shares will be Vested Shares. If Stockholder has continuously been employed by the Company or any Affiliate, at all times from the Effective
Date until [                    ] (the “First Vesting Date”), then on the First Vesting Date, and additional
[1/16th] of the Shares will become Vested Shares; and thereafter, for so long (and only for so long) as Stockholder remains continuously employed by the Company or any Affiliate at all times after
the First Vesting Date, on the last day of each succeeding three month period elapsed after the First Vesting Date an additional [1/16th] of the Shares will become Vested Shares. No Unvested
Shares will become Vested Shares after the Termination Date. If the application of the vesting percentage results in a fractional Share, such fraction shall be rounded down to the nearest whole Share. 

4.3. Adjustments. The number of Shares that are Vested Shares or Unvested Shares will be proportionally adjusted to reflect any
stock dividend, stock split, reverse stock split or recapitalization of the common stock of the Company occurring after the Effective Date. 

4.4. Repurchase Option on Unvested Shares at $0.0001 Per Share. At any time within ninety (90) days after the Termination
Date, the Company or its assignee shall have the right (but not the obligation), to repurchase any or all of the Unvested Shares (the “Unvested Share Repurchase Option”) by giving Stockholder written notice of exercise of the
Unvested Share Repurchase Option. The Company and/or its assignee(s) will then have the option to repurchase from Stockholder (or from Stockholder’s personal representative as the case may be) any or all of the Unvested Shares at $0.0001 per
Share, as adjusted to reflect any stock dividend, stock split, reverse stock split or recapitalization of the common stock of the Company occurring after the Effective Date (the “Unvested Share Repurchase Price”). The
Unvested Share Repurchase Price will be payable, at the option of the Company and/or its assignee(s), as the case 

  
 4 

 
may be, by check or by cancellation of all or a portion of any outstanding indebtedness owed by Stockholder to the Company (or to such assignee) or by any combination thereof. The Unvested Share
Repurchase Price will be paid without interest within ninety (90) days after the Company gives the Stockholder written notice of the exercise of the Unvested Share Repurchase Option. 

4.5. Repurchase Option on Vested Shares at $0.0001 Per Share. If Stockholder ceases to be employed by the Company or an
Affiliate due to termination by the Company or an Affiliate for Cause (as defined below), then at any time within ninety (90) days after the Termination Date, the Company or its assignee, shall have the right (but not the obligation), to
repurchase any or all of the Vested Shares (the “Vested Share Repurchase Option”) by giving Stockholder written notice of exercise of the Vested Share Repurchase Option. The Company and/or its assignee(s) will then have the
option to repurchase from Stockholder (or from Stockholder’s personal representative as the case may be) any or all of the Vested Shares at $0.001 per Share, as adjusted to reflect any stock dividend, stock split, reverse stock split or
recapitalization of the common stock of the Company occurring after the Effective Date (the “Vested Share Repurchase Price”). The Vested Share Repurchase Price will be payable, at the option of the Company and/or its
assignee(s), as the case may be, by check or by cancellation of all or a portion of any outstanding indebtedness owed by Stockholder to the Company (or to such assignee) or by any combination thereof. The Vested Share Repurchase Price will be paid
without interest within ninety (90) days after the Company gives the Stockholder written notice of the exercise of the Vested Share Repurchase Option. 

For purposes of this Section 4.5, “Cause” shall mean the termination of Stockholder’s status as an employee, a director or
consultant (as applicable) of the Company or an Affiliate for any of the following reasons, as determined by the Board of Directors of the Company; provided, that, with respect to a Stockholder that is party to an agreement with the Company where a
termination for cause is defined in such agreement, the definition in such agreement shall govern the determination under this Section 4.5:(i) Stockholder commits a material breach of any consulting, employment, noncompetition, confidentiality
or similar agreement with the Company or an Affiliate, as determined under such agreement; (ii) Stockholder is convicted (including a trial, plea of guilty or plea of nolo contendere) for committing an act of fraud, embezzlement, theft, or
other act constituting a felony; or (iii) Stockholder willfully engages in gross misconduct or willfully violates the policies of the Company or an Affiliate in a manner that is materially and demonstrably injurious to the Company and/or the
Affiliate. However, no act, or failure to act, on the grantee’s part shall be considered “willful” unless done, or omitted to be done, by the grantee not in good faith and without reasonable belief that the grantee’s action or
omission was in the best interest of the Company or the Affiliate. 
 4.6. Right of Termination Unaffected. Nothing in this
Agreement will be construed to limit or otherwise affect in any manner whatsoever the right or power of the Company (or any Affiliate) to terminate Stockholder’s employment with the Company (or any Affiliate) at any time for any reason or no
reason, with or without cause. 
 5. RIGHTS AS OWNER OF SHARES. Subject to the terms and conditions of this Agreement,
Stockholder will have all of the rights to the Shares from and after the date that Stockholder acquired them in the Conversion until such time as Stockholder disposes of the Shares or the Company and/or its assignee(s) exercise(s) the Repurchase
Option. Upon an 

  
 5 

 
exercise of the Repurchase Option, Stockholder will have no further rights as a holder of the Shares so purchased upon such exercise, except the right to receive payment for the Shares so
purchased in accordance with the provisions of this Agreement, and Stockholder will promptly surrender the stock certificate(s) evidencing the Shares so purchased to the Company for transfer or cancellation. 

6. ESCROW. As security for Stockholder’s faithful performance of this Agreement, Stockholder
agrees, immediately upon receipt of the stock certificate(s) evidencing the Shares, to deliver such certificate(s), together with the Stock Powers attached in the form of Exhibit 1 hereto executed by Stockholder and by Stockholder’s
spouse, if any (with the date, transferee, stock certificate number and number of Shares left blank), to the Secretary of the Company or other designee of the Company (the “Escrow Holder”), who is hereby appointed to hold
such certificate(s) and Stock Powers in escrow and to take all such actions and to effectuate all such transfers and/or releases of such Shares as are in accordance with the terms of this Agreement. Escrow Holder will act solely for the Company as
its agent and not as a fiduciary. Stockholder and the Company agree that Escrow Holder will not be liable to any party to this Agreement (or to any other party) for any actions or omissions unless Escrow Holder is grossly negligent or intentionally
fraudulent in carrying out the duties of Escrow Holder under this Agreement. Escrow Holder may rely upon any letter, notice or other document executed with any signature purported to be genuine and may rely on the advice of counsel and obey any
order of any court with respect to the transactions contemplated by this Agreement.  
 7. TAX CONSEQUENCES.
STOCKHOLDER UNDERSTANDS THAT STOCKHOLDER MAY SUFFER ADVERSE TAX CONSEQUENCES AS A RESULT OF STOCKHOLDER’S PURCHASE OR DISPOSITION OF THE SHARES. STOCKHOLDER REPRESENTS (a) THAT STOCKHOLDER HAS CONSULTED WITH A TAX ADVISER THAT STOCKHOLDER
DEEMS ADVISABLE IN CONNECTION WITH THE PURCHASE OR DISPOSITION OF THE SHARES AND (b) THAT STOCKHOLDER IS NOT RELYING ON THE COMPANY FOR ANY TAX ADVICE. Stockholder hereby acknowledges that Stockholder has been informed that, in addition to
receiving taxable income upon the receipt of any Shares paid for by the cancellation of compensation for services rendered, unless an election is filed by the Stockholder with the Internal Revenue Service (and, if necessary, the proper state taxing
authorities) within 30 days after the acquisition of the Shares to be effective, electing pursuant to Section 83(b) of the Internal Revenue Code (and similar state tax provisions, if applicable) to be taxed currently on any difference
between the purchase price of the Shares (“Purchase Price”) and their fair market value on the date of purchase, there will be a recognition of taxable income to the Stockholder, measured by the excess, if any, of the fair
market value of the Shares, at the time they cease to be Unvested Shares, over the Purchase Price for such Shares. Stockholder represents that Stockholder has consulted any tax advisors Stockholder deems advisable in connection with
Stockholder’s acquisition of the Shares and the filing of the election under Section 83(b) and similar tax provisions. A form of Election under Section 83(b) is attached hereto as Exhibit 2 for reference. STOCKHOLDER
HEREBY ASSUMES ALL RESPONSIBILITY FOR FILING SUCH ELECTION AND PAYING ANY TAXES RESULTING FROM SUCH ELECTION OR FROM FAILURE TO FILE THE ELECTION AND PAYING TAXES RESULTING FROM THE LAPSE OF THE REPURCHASE RESTRICTIONS ON THE UNVESTED SHARES. 

  
 6 

 8. RESTRICTIVE LEGENDS AND STOP-TRANSFER ORDERS. Stockholder understands and agrees
that the Company will place the legends set forth below or similar legends on any stock certificate(s) evidencing the Shares, together with any other legends that may be required by state or federal securities laws, the Company’s Certificate of
Incorporation or Bylaws, any other agreement between Stockholder and the Company or any third party: 
 THE SECURITIES REPRESENTED HEREBY
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND
RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF
THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND
ANY APPLICABLE STATE SECURITIES LAWS. 
 THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER AS
SET FORTH IN THE ISSUER’S EQUITY INCENTIVE PLAN AND THE STOCK RESTRICTION AGREEMENT RELATING TO THESE SHARES, COPIES OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER, SUCH TRANSFER RESTRICTIONS ARE BINDING ON TRANSFEREES OF THESE
SHARES. 
 Stockholder agrees that, to ensure compliance with the restrictions imposed by this Agreement, the Company may issue appropriate
“stop-transfer” instructions to its transfer agent, if any, and if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records. The Company will not be required (a) to transfer on
its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this Agreement or (b) to treat as owner of such Shares, or to accord the right to vote or pay dividends, to any Stockholder or other
transferee to whom such Shares have been so transferred. 
 9. COMPLIANCE WITH LAWS AND REGULATIONS. The issuance and transfer
of the Shares will be subject to and conditioned upon compliance by the Company and Stockholder with all applicable state and federal laws and regulations and with all applicable requirements of any stock exchange or automated quotation system on
which the Company’s Common Stock may be listed or quoted at the time of such issuance or transfer. 
 10. GENERAL
PROVISIONS. 
 10.1. Notices. Any and all notices required or permitted to be given to a party pursuant to the
provisions of this Agreement will be in writing and will be effective and deemed to provide such party sufficient notice under this Agreement on the earliest of the following: (a) at the time of personal delivery, if delivery is in person;
(b) one (1) business day after deposit with an express overnight courier for United States deliveries, or two (2) business days after such deposit for deliveries outside of the United States; or (c) three (3) business days
after deposit in the United States mail by certified mail (return receipt requested) for United States deliveries. 

  
 7 

 
All notices for delivery outside the United States will be sent by express courier. All notices not delivered personally will be sent with postage and/or other charges prepaid and properly
addressed to the party to be notified at the address set forth below the signature lines of this Agreement or at such other address as such other party may designate by one of the indicated means of notice herein to the other party hereto. A
“business day” shall be a day, other than Saturday or Sunday, when the banks in the city of San Francisco are open for business. 

10.2. Further Assurances. The parties agree to execute such further documents and instruments and to take such further actions
as may be reasonably necessary to carry out the purposes and intent of this Agreement. 
 10.3. Titles and Headings. The
titles, captions and headings of this Agreement are included for ease of reference only and will be disregarded in interpreting or construing this Agreement. Unless otherwise specifically stated, all references herein to “sections” and
“exhibits” will mean “sections” and “exhibits” to this Agreement. 
 10.4. Governing Law. This
Agreement will be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to that body of laws pertaining to conflict of laws. 

10.5. Assignments; Successors and Assigns. The Company may assign any of its rights and obligations under this Agreement,
including but not limited to its rights to repurchase Shares under the Repurchase Option. Any assignment of rights and obligations by any other party to this Agreement requires the Company’s prior written consent. This Agreement, and the rights
and obligations of the parties hereunder, will be binding upon and inure to the benefit of their respective successors, assigns, heirs, executors, administrators and legal representatives. 

10.6. Entire Agreement. This Agreement and the documents referred to herein constitute the entire agreement and understanding of
the parties with respect to the subject matter of this Agreement, and supersede all prior understandings and agreements, whether oral or written, between or among the parties hereto with respect to the specific subject matter hereof. 

10.7. Amendment and Waivers. This Agreement may be amended only by a written agreement executed by each of the parties hereto.
No amendment of or waiver of, or modification of any obligation under this Agreement will be enforceable unless set forth in a writing signed by the party against which enforcement is sought. Any amendment effected in accordance with this section
will be binding upon all parties hereto and each of their respective successors and assigns. No delay or failure to require performance of any provision of this Agreement shall constitute a waiver of that provision as to that or any other instance.
No waiver granted under this Agreement as to any one provision herein shall constitute a subsequent waiver of such provision or of any other provision herein, nor shall it constitute the waiver of any performance other than the actual performance
specifically waived. 
 10.8. Severability. If any provision of this Agreement is determined by any court or arbitrator of
competent jurisdiction to be invalid, illegal or unenforceable in any respect, such provision will be enforced to the maximum extent possible given the intent of the parties 

  
 8 

 
hereto. If such clause or provision cannot be so enforced, such provision shall be stricken from this Agreement and the remainder of this Agreement shall be enforced as if such invalid, illegal
or unenforceable clause or provision had (to the extent not enforceable) never been contained in this Agreement. Notwithstanding the forgoing, if the value of this Agreement based upon the substantial benefit of the bargain for any party is
materially impaired, which determination as made by the presiding court or arbitrator of competent jurisdiction shall be binding, then both parties agree to substitute such provision(s) through good faith negotiations. 

10.9. Counterparts; Facsimile Signatures. This Agreement may be executed in any number of counterparts, each of which when so
executed and delivered will be deemed an original, and all of which together shall constitute one and the same agreement. This Agreement may be executed and delivered by facsimile or electronic transmission and upon such delivery the facsimile or
electronic signature will be deemed to have the same effect as if the original signature had been delivered to the other party. 
 [Signature
page follows] 

  
 9 

 IN WITNESS WHEREOF, the Company has caused this Stock Restriction Agreement to be executed
by its duly authorized representative and Stockholder has executed this Agreement, each as of the Effective Date. 
  

									
	COMPANY: AEGLEA BIOTHERAPEUTICS, INC.				STOCKHOLDER:
					
							[Name]		
					
	By:		  
				By:		  

					
	Name:		David Lowe				Address:		  

				
	Title:		CEO				  

				
	Address:		901 S. MoPac Expressway				  

			Barton Oaks Plaza One, Suite 250						
			Austin, Texas 78746						

 LIST OF EXHIBITS 
  

			
	Exhibit 1:		Stock Power and Spouse Consent
	Exhibit 2:		Election Under Section 83(b) of the Internal Revenue Code

 EXHIBIT 1 

STOCK POWER AND ASSIGNMENT 

SEPARATE FROM CERTIFICATE 
 FOR VALUE
RECEIVED and pursuant to that certain Stock Restriction Agreement dated as of March     , 2015 (the “Agreement”), the undersigned hereby sells, assigns and transfers unto
                                        ,
                 shares of the Common Stock, $0.0001 par value per share, of Aeglea BioTherapeutics, Inc., a Delaware corporation (the
“Company”), standing in the undersigned’s name on the books of the Company represented by Certificate No(s).
                     delivered herewith, and does hereby irrevocably constitute and appoint the Secretary of the Company as the undersigned’s
attorney-in-fact, with full power of substitution, to transfer said stock on the books of the Company. THIS ASSIGNMENT MAY ONLY BE USED AS AUTHORIZED BY THE AGREEMENT AND ANY EXHIBITS THERETO. 

Dated:                      

 

	
	STOCKHOLDER
	
	  

	(Signature)
	
	  

	(Please Print Name)
	
	  

	(Spouse’s Signature, if any)
	
	  

	(Please Print Spouse’s Name)

 Instructions to Stockholder: Please do not fill in any blanks other than the signature line. The
purpose of this Stock Power and Assignment is to enable the Company and/or its assignee(s) to acquire the shares upon exercise of its “Repurchase Option” and “Right of First Refusal” set forth in the Agreement without requiring
additional signatures on the part of the Stockholder or Stockholder’s Spouse, if any. 

 SPOUSE CONSENT 

The undersigned spouse of
                                        
(“Stockholder”) has read, understands and hereby approves all the terms and conditions of the Stock Restriction Agreement dated March     , 2015 (the “Agreement”), by and between
Stockholder and Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”). 
 I hereby agree to be
irrevocably bound by all the terms and conditions of the Agreement (including but not limited to the Company’s Repurchase Option and the Right of First Refusal contained therein) and further agree that any community property interest I may have
in the shares of the Company’s Common Stock that are held by Stockholder and are subject to the Agreement (the “Shares”) will be similarly bound by the Agreement. 

I hereby appoint Stockholder as my attorney-in-fact, to act in my name, place and stead with respect to any amendment of the Agreement. 

Dated:                      

 

			
			Signature of Spouse [Sign Here]
		
			Name of Spouse [Please Print]
		
	 ̈		Check this box if you do not have a spouse.

 EXHIBIT 2 

ELECTION UNDER SECTION 83(b) OF THE 

INTERNAL REVENUE CODE 

 ELECTION UNDER SECTION 83(b) OF THE 

INTERNAL REVENUE CODE 
 The undersigned
Taxpayer hereby elects, pursuant to Section 83(b) of the Internal Revenue Code of 1986, as amended, to include the excess, if any, of the fair market value of the property described below at the time of transfer over the amount paid for such
property, as compensation for services in the calculation of: (1) regular gross income; (2) alternative minimum taxable income; or (3) disqualifying disposition gross income, as the case may be. 

 

							
	1.		TAXPAYER’S NAME:		  
		
				
			TAXPAYER’S ADDRESS:		  
		
					  
		
				
			SOCIAL SECURITY NUMBER:		  
		
		
	2.		The property with respect to which the election is made is described as follows:                 shares of Common Stock, par value
$0.0001 per share, of Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), which is Taxpayer’s employer or the corporation for whom the Taxpayer performs services.
		
	3.		The date on which the shares were transferred was             ,          and this election is made for the calendar
year 2015.
		
	4.		The shares are subject to the following restrictions: The Company may repurchase all or a portion of the shares at the Taxpayer’s original purchase price per share, under certain conditions at the time of
Taxpayer’s termination of employment or services.
		
	5.		The fair market value of the shares (without regard to restrictions other than restrictions which by their terms will never lapse) was $         per share x
                 shares = $        .
		
	6.		The amount paid for such shares was $         per share x                  shares =
        .
		
	7.		The Taxpayer has submitted a copy of this statement to the Company.
		
	8.		The amount to include in gross income is $        .

 THIS ELECTION MUST BE FILED WITH THE INTERNAL REVENUE SERVICE (“IRS”), AT THE OFFICE WHERE
THE TAXPAYER FILES ANNUAL INCOME TAX RETURNS, WITHIN 30 DAYS AFTER THE DATE OF TRANSFER OF THE SHARES, AND MUST ALSO BE FILED WITH THE TAXPAYER’S INCOME TAX RETURNS FOR THE CALENDAR YEAR. THE ELECTION CANNOT BE REVOKED WITHOUT THE
CONSENT OF THE IRS. 
  

							
	Dated:				
                     
                    
		
					[NAME]EX-10.9

 Exhibit 10.9 

SPONSORED RESEARCH AGREEMENT NO. UTA13-001113 

This Sponsored Research Agreement (“Agreement”) is made between The University of Texas at Austin, Austin, Texas (“University”), an
institution of higher education created by the Constitution and law of the State of Texas under The University of Texas System (“System”) and Aeglea Development Company, Inc., AERase, Inc., AEMase, Inc., AECase, Inc., AE4ase, Inc., AE5ase,
Inc., and AE6ase, Inc., all Delaware C corporations with their principal place of business at 815 A Brazos St., #101, Austin TX 78701 (each a “Sponsor Entity” and collectively, “Sponsor”). Aeglea Development Company, Inc. may be
referred to herein as the “Funding Sponsor” or “Sponsor Entity” as appropriate. 
 RECITALS 

A. Sponsor desires that University perform certain research work hereinafter described and is willing to advance funds to sponsor such
research; 
 B. Sponsor desires to obtain certain rights to patents and technology developed during the course of such research with a view
to profitable commercialization of such patents and technology for the Sponsor’s benefit; and 
 C. University is willing to perform
such research and to grant rights to such patents and technology; 
 NOW THEREFORE, in consideration of the mutual covenants and promises herein contained,
the University and Sponsor agree as follows: 
 1. EFFECTIVE DATE 

This Agreement shall be effective as of December 1, 2013 (the “Effective Date”). 

2. RESEARCH PROGRAM 

2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A (“Research Program”), and will furnish the
facilities necessary to carry out said Research Program. The Research Program will be under the direction of Professor George Georgiou (“Principal Investigator”), or (his or her) successor as mutually agreed to by the parties and
will be conducted by the Principal Investigator at the University. University agrees to use reasonable efforts to perform the Research Program in a manner consistent with its status as an institution of higher education. University shall perform the
Research Program in accordance with (i) established University policies and procedures, including, but not limited to, policies and procedures applicable to research involving human subjects, human tissues or organs, laboratory animals, and
hazardous agents and materials, and (ii) all applicable federal, state, and local laws, rules, regulations and guidelines. 
  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

 2.2 The Research Program shall be performed during the period from the Effective Date for a period of 12 month
periods thereafter (the “Research Term”). Funding Sponsor shall have the option of extending the Research Program under mutually agreeable support terms. 

2.3 Sponsor understands that University’s primary mission is education and advancement of knowledge, and consequently the Research Program will be
designed to carry out that mission. The manner of performance of the Research Program shall be determined solely by the Principal investigator. University does not guarantee specific results, and the Research Program will be conducted only on a
reasonable efforts basis. 
 2.4 University will keep accurate financial and scientific records relating to the Research Program and will make such records
available to Sponsor or its authorized representative throughout the Term of the Agreement during normal business hours upon reasonable notice. 
 2.5
Sponsor understands that University may be involved in similar research on behalf of itself and others. University shall be free to continue such research provided that it is conducted separately from the Research Program hereinafter defined, and
Sponsor shall not gain any rights via this Agreement to such other research. 
 2.6 University does not guarantee that any patent rights will result from
the Research Program, that the scope of any patent rights obtained will cover Sponsor’s commercial interests, or that any such patent rights will be free of dominance by other patents, including those based upon inventions made by other
inventors in The University of Texas System independent of the Research Program. 
 3. COMPENSATION 

3.1 Sponsor obligations under this Article 3 shall be limited to Funding Sponsor. 

3.2 As consideration for the performance by University of its obligations under this Agreement, Funding Sponsor will pay the University an amount equal to its
reasonable, documented expenditures and reasonable overhead (such overhead to not exceed the rate set forth in University’s indirect rate agreement with the U.S. Federal Government) in conducting the Research Program subject to a maximum
expenditure limitation of $386,252, provided that in any and all events, the amounts charged by University shall not, without Funding Sponsor’s prior written consent, exceed the amount. Payments shall be made as follows (subject to the possible
later return of funds if uncommitted and unexpended, under Section 3.3): 
  

	 	(a)	Upon execution of all parties to the Agreement: $193,126; 

  

	 	(b)	$96,563 by March 31, 2014; and 

  

	 	(c)	$96,563 by June 30, 2014 

 Payments should be made within 30 days of the receipt of an undisputed invoice
sent via mail and email and payable to The University of Texas at Austin, make reference to the Principal Investigator, Agreement number and title of the Research Program funded under this Agreement, and submitted to the address in
Article 3.5. 
  
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  
 2 

 3.3 University shall maintain all Research Program funds in a separate account and shall expend such funds for
wages, supplies, equipment, travel, and other operational expenses in connection with the Research Program. It is understood that funds of the Research Program which are not used in a particular quarter may be used in subsequent quarters, and that
the Principal Investigator may transfer funds within the budget as needed without Funding Sponsor’s approval, as long as such transfers do not effect a change in the scope of work of the Research Program. It is also understood that subject to
Section 10.4, uncommitted and unexpended funds remaining at the termination of the Agreement shall be returned to Funding Sponsor within ninety (90) days of the effective date of termination; provided, however, that the parties agree that
in order to minimize administrative close-out expenses, if funds remaining upon termination or expiration of the Agreement equal $250.00 or less, such funds shall be retained by the University and disposed of in accordance with University policy.

 3.4 University shall retain title to all equipment purchased and/or fabricated by it with funds provided by Funding Sponsor under this Agreement. 

3.5 
  

			
	 Checks shall be made payable to University

and sent to:
		 Invoices shall be mailed and emailed to

Funding Sponsor at:

	 The University of Texas at Austin

Office of Accounting — SPAA
		 Aeglea Development Company

815-A Brazos, Ste_#101

	 P.O. Box 7159
		 Austin TX 78701

	 Austin, Texas 78713-7159
		 Attn: David G. Lowe

	 (512) 471-6231
		 Phone: [phone]

	Tax ID #: 746000203		 Fax: (866) 873-2149

			 E-mail: [email]

 4. CONSULTATION AND REPORTS 

4.1 Sponsor’s designated representative (“Designated Representative”) for consultation and communications with the Principal Investigator shall
be David G. Lowe or such other person as Sponsor may from time to time designate in writing to University and the Principal Investigator. 
 4.2
During the term of the Agreement, Sponsor’s representatives may consult informally with University’s representatives regarding the project, both personally and by telephone. Access to work carried on in University laboratories in the
course of these investigations shall be entirely under the control of University personnel but shall be made available on a reasonable basis. 
 4.3 The
Principal Investigator will make up to one oral report(s) monthly and quarterly written reports accompanied by a presentation describing the results and accomplishments obtained and plans going forward. Changes or amendments to the Research Program
if any, will be discussed at the quarterly meeting and described in a written amendment to the Research 
  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

  
 3 

 
Program as requested by Sponsor’s Designated Representative. The Principal Investigator shall also submit a comprehensive final report within ninety (90) days of termination of the
Agreement which shall consist of a report of all activities undertaken and accomplishments achieved through the Research 

5. PUBLICITY 

Neither party shall make reference to the other in a press release or any other written statement in connection with work performed under this Agreement, if
it is intended for use in the public media, except as required by the Texas Public Information Act or other law or regulation. University, however, shall have the right to acknowledge Sponsor’s support of the investigations under this Agreement
in scientific or academic publications and other scientific or academic communications, without Sponsor’s prior approval. In any statements, the scope and nature of participation shall be described accurately and appropriately. 

6. PUBLICATION AND ACADEMIC RIGHTS: CONFIDENTIALITY 

6.1 University and the Principal Investigator have the right to publish or otherwise publicly disclose information gained in the course of this Agreement,
except for Sponsor’s Confidential Information. In order to avoid loss of patent rights as a result of premature public disclosure of patentable information, University will submit (a) any prepublication materials and (b) a copy of any
materials to be publicly disclosed to Sponsor for review and comment thirty (30) days in advance of its planned submission for publication or public disclosure to the extent possible, but in the case of any requests under the Texas Public
Information Act, prior to release of any information to the requestor. Funding Sponsor may request in writing, and University shall agree to, (i) the deletion of any Confidential Information provided by Sponsor, and (iii) a delay of such
proposed publication or public disclosure for an additional period, not to exceed sixty (60) days, in order to protect the potential patentability of any technology described therein. Funding Sponsor shall be entitled to receive in any such
publication or public disclosure an acknowledgment of its sponsorship of the Research Program. University shall have final authority to determine the scope and content of any publications or disclosures provided that in no event shall any
publication or disclosure include Sponsor’s Confidential Information. 
 6.2 It is anticipated that inventions or discoveries arising from the Research
Program (“Inventions”) shall be discussed with Funding Sponsor concurrently with their reduction to practice by the Principal Investigator. It is understood that the University investigators may discuss the research being performed under
this Agreement with other University investigators but shall not reveal Confidential Information to such investigators unless such investigators have signed a nondisclosure agreement. 

6.3 In conjunction with the Research Program, Sponsor may wish to disclose certain of its confidential and/or proprietary information (“Confidential
Information”) to University during the term of this Agreement. Confidential Information will be transmitted in writing and clearly marked “Confidential,” “Proprietary,” or similarly, or if disclosed orally will be reduced to

  
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  
 4 

 
writing by Disclosing Party, clearly marked “Confidential,” “Proprietary,” or similarly, and transmitted to the Contact Person of Receiving Party within thirty (30) days
after oral disclosure. No license under or title to any invention, patent, trademark, trade name or other intellectual property or other rights or interests in the Confidential Information now or hereafter owned by or controlled by any Party is
granted either expressly, by implication, estoppel or otherwise by the Agreement. All Confidential Information is provided “AS IS” and without warranty, express or implied, of any kind. 

University will use Confidential Information solely for the purpose of conducting the Research Program, and shall use reasonable efforts to
prevent the disclosure of Confidential Information to third parties during the term of this Agreement and for a period of five (5) years after its expiration or termination. If required, University may disclose Confidential Information to a
governmental authority or by order of a court of competent jurisdiction, provided that such disclosure is subject to all applicable governmental or judicial protection available for like information and reasonable advance notice is given to Funding
Sponsor. University’s obligations with respect to Confidential Information shall not apply to information that (a) is already in University’s possession at the time of disclosure; (b) is or later becomes part of the public domain
through no fault of University; (c) is received on a non-confidential basis from a third party having no obligations of confidentiality or nonuse to University’s; or (d) independently developed by University. Notwithstanding the
foregoing, University may retain one archival copy of the Confidential Information received in a secure location to be used solely to determine its obligations under the Agreement. 

The Parties agree that, in the event of breach or threatened breach or intended breach of the Agreement, each Party, in addition to any other
rights and remedies available to it at law or in equity, may seek injunctive or equitable relief without the necessity of posting bond or proving that it has no adequate remedy at law. 

7. PATENTS, COPYRIGHTS AND TECHNOLOGY RIGHTS 

7.1 Title to Inventions conceived and reduced to practice solely by University shall reside in University (“University Inventions”). Title to all
Inventions conceived and reduced to practice solely by Sponsor shall reside in Sponsor (“Sponsor Inventions”). Title to all inventions and discoveries conceived and reduced to practice jointly by Sponsor and University shall reside jointly
in Sponsor and University (“Joint Inventions”). University hereby grants to Sponsor an exclusive first option to negotiate a royalty- bearing exclusive license for any invention or discovery that is conceived or reduced to practice during
the term of this Agreement directly resulting from the performance of research hereunder to the extent that University is able to do so under applicable law. It is contemplated that, in the majority of instances, Sponsor will be asked to determine
whether it will exercise its option prior to the filing of the first patent application. University reserves for itself a royalty-free, irrevocable license to make and use such University Inventions and Joint Inventions for its own research and
educational purposes, but not for commercial purposes during the option period. If a University Invention or Joint Invention arises from the Research Program, the Principal Investigator shall promptly submit an invention 

 
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  
 5 

 
disclosure (http://www.otc.utexas.edu/InventorForms.jsp) to University’s Office of Technology Commercialization (“OTC”). University will provide to Sponsor a full copy of
such disclosure promptly after such disclosure is received by OTC. Sponsor may review (and University shall provide to Sponsor) any and all patentability and freedom to operate opinions that have been commissioned by the University. A Sponsor Entity
shall then have ninety (90) days from receipt of such disclosure of any University Invention or Joint Invention to notify University of its desire to enter into such a license agreement, and a non-binding term sheet and thereafter a license
agreement shall be negotiated in good faith within a period not to exceed six (6) months (“License Option Period”) from the applicable Sponsor Entity’s notification to University of its desire to enter into a license agreement,
or such period of time as the parties shall mutually agree in writing. The parties agree to negotiate, in good faith, a license agreement with terms and conditions substantially similar to existing license agreements between the parties, to the
extent allowed by current law, University policy, and reasonable updates to financial terms. During the License Option Period, University agrees that it will not offer its rights in University Inventions or Joint Inventions to any third party or
negotiate with third parties with respect to those rights. If the parties fail to enter into a license agreement within the License Option Period under the provisions of this Section 7.1, University rights in University Inventions and Joint
Inventions shall be disposed of in accordance with University policies with no further obligations to Sponsor. 
 7.2 “Background Intellectual
Property” (“BIP”) means intellectual property and the legal rights therein (including, but not limited to, inventions, patent applications, patents, copyrights, and any information embodying proprietary data such as technical data and
computer software) of University developed or created by Principal Investigator(s) before the Effective Date of the Research Program and necessary for the full exercise of all intellectual property which is related to the Research Program.
University BIP is listed in Attachment B of this Agreement. The Parties agree that nothing in this Agreement grants either Party any rights to any background intellectual property of the other Party created before the Effective Date of the
Agreement. 
 7.3 The applicable Sponsor Entity has the right to elect to have patent applications filed on any University Invention or Joint Invention, and
if it does so, then such Sponsor Entity shall reimburse University for all documented, out-of-pocket patent expenses incurred by University, including those for patentability opinions, within thirty (30) days of such Sponsor Entity’s
receipt of an invoice from University. Such patent expenses shall include, but not be limited to, the cost of any prior activities investigating patentability of said invention before exercise of the option, such as search and opinion for
patentability, that may have been performed by University pursuant to its arrival at a judgment of commercially exploitable status. Following expiration of the License Option Period, and in the event that University grants a license to any
University Inventions to a third party (the “Third Party License”), University shall pay to the applicable Sponsor Entity its reasonable costs incurred in connection with the preparation, filing, prosecution and maintenance of the licensed
University Inventions or Joint Inventions paid under the Third Party License with the following priority for payment: i) in one full payment from the fees reimbursed to University by a third party under the executed license; or if necessary, ii) on
a quarterly basis, a royalty (the “Third Party Royalty”) equal to one hundred percent (100%) of 
  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

  
 6 

 
University’s net licensing revenue attributable to the Third Party License (including license fees, royalties, revenue sharing, milestone payments and other monetary payments) until such
time as University has paid to such Sponsor Entity aggregate Third Party Royalties equal to such Sponsor Entity’s reasonable costs incurred in connection with the preparation, filing, prosecution and maintenance of the licensed University
Inventions. 
 7.4 At its discretion, University may allow the applicable Sponsor Entity to instruct Prosecution Counsel directly for University Inventions
and Joint Inventions, provided, that prior written approval is obtained and the Prosecution Counsel remains counsel to the University with an appropriate contract (and shall not jointly represent such Sponsor Entity unless requested by such Sponsor
Entity and approved by University, not to be unreasonably denied, and an appropriate engagement letter and conflict, waiver are in effect). If such Sponsor Entity wishes to instruct Prosecution Counsel directly or change Prosecution Counsel, such
Sponsor Entity may request to do so by following the University’s procedures for such. Subject to the terms herein University reserves in its sole discretion the ability to change Prosecution Counsel and to approve or disapprove any requested
changes by such Sponsor Entity. The Parties agree that they share a common legal interest to get valid enforceable patents in strategically important countries and that both Parties will maintain as privileged all information received pursuant to
this Section 7. Each Party agrees to cooperate fully in the preparation, filing, and prosecution of any patent and any joint patent, as described herein. Such cooperation includes without limitation executing all papers and instruments, or requiring
its representatives to execute such papers and instruments, so as to effectuate the ownership of such intellectual property rights. 
 7.5 Notwithstanding
anything to the contrary set forth herein, University hereby grants to Sponsor a perpetual, irrevocable, worldwide, non-exclusive, royalty free right and license, with the right to sublicense to third parties through multiple tiers, to use the Data
and Results for any and all purposes. Data and Results mean all data, information and results arising from the Research Program that are included in the Research Program deliverables but are not inventions and discoveries for which a patent
invention disclosure is made. 
 8. LIABILITY 

8.1 Sponsor agrees to defend (and subject to the statutory duties of the Texas State Attorney General to defend University, if applicable),indemnify and hold
harmless System, University, their Regents, officers, agents and employees from any liability, loss or damage they may suffer as a result of third party claims, demands, costs or judgments against them arising out of the activities to be carried out
pursuant to the obligations of this Agreement, including but not limited to the use by Sponsor of the results obtained from the activities performed by University under this Agreement; provided, however, that the following is excluded from
Sponsor’s obligation to defend, indemnify and hold harmless: 
  

	 	(a)	the negligent failure of University to substantially comply with any applicable FDA or other governmental requirements; or 

  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

  
 7 

	 	(b)	the negligence or willful malfeasance of any Regent, officer, agent or employee of University or System 

 8.2
To the extent authorized by the constitution and laws of the State of Texas, University agrees to defend, indemnify and hold harmless Sponsor, its officers, agents and employees from any liability, loss or damage they may suffer as a result of third
party claims, demands, costs or judgments against them arising out of (i) the negligence or willful malfeasance of any Regent, officer, agent or employee of University or System or (ii) breach of this Agreement by any Regent, officer,
agent or employee of University or System, provided, however, that University shall not be obligated to hold harmless any Sponsor Indemnitee from claims arising out of the negligence or willful malfeasance of Sponsor. 

8.3 Both parties agree that upon receipt of a notice of claim or action arising out of the activities to be carried out pursuant to the Research Program, the
party receiving such notice will notify the other party promptly. 
 9. INDEPENDENT CONTRACTOR 

For the purposes of this Agreement and all services to be provided hereunder, the parties shall be, and shall be deemed to be, independent contractors and not
agents or employees of the other party. Neither party shall have authority to make any statements, representations or commitments of any kind, or to take any action which shall be binding on the other party, except as may be expressly provided for
herein or authorized in writing. 
 10. TERM AND TERMINATION 

10.1 This Agreement shall commence on the Effective Date and extend until the end of the Research Term, unless sooner terminated in accordance with the
provisions of this Article 10. 
 10.2 This Agreement may be terminated by Sponsor for its convenience upon sixty (60) days prior written notice to
University. 
 10.3 In the event that either party shall be in default of its material obligations under this Agreement and shall fail to remedy such
default within sixty (60) days after receipt of written notice thereof, this Agreement may be terminated at the option of the party not in default upon expiration of the sixty (60) day period. 

10.4 This Agreement shall terminate automatically and immediately if Sponsor becomes bankrupt or insolvent and/or enters receivership or trusteeship, whether
by voluntary act of Sponsor or otherwise. 
 10.5 Termination or cancellation of this Agreement shall not affect the rights and obligations of the parties
accrued prior to termination. Upon termination, (i) Sponsor shall pay University for all reasonable expenses incurred or committed to be expended due pursuant to Section 3 hereof as of the effective termination date, including salaries for
appointees for the remainder of their 
  
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  
 8 

 
appointment and (ii) University shall return to Sponsor or destroy any Confidential Information in its possession or control, subject to University’s right to keep an archival copy
pursuant to Section 6.3. 
 10.6 Any provisions of this Agreement which by their nature extend beyond termination shall survive such termination
including, without limitation, Sections 6 and 7. 
 10.7 This Agreement will terminate with respect to any individual Sponsor Entity at such time as it is
no longer a wholly owned subsidiary of Aeglea BioTherapeutics Holdings LLC and upon such a termination the respective Sponsor Entity shall be removed as a party to this Agreement. Sponsor will provide prompt written notice of the same to University.

 11. ATTACHMENTS 

Attachments A and B are incorporated and made a part of this Agreement for all purposes. 

12. USE OF HUMAN SUBJECTS (if applicable) 

12.1 University will conduct all research in accordance with Federal Wide Assurance #2030, written protocol, applicable law, and University’s ethical
standards. In the event a research participant has a research related injury neither University nor the Sponsor are responsible for any resulting medical care. 

12.2 If the Sponsor is responsible for monitoring research, then the Sponsor must alert University’s Institutional Review Board (“IRB”) when
research findings: 
  

	 	(a)	Affect the safety of the participants 

  

	 	(b)	Affect the willingness of research participants to continue participation 

  

	 	(c)	Influence the conduct of the study 

  

	 	(d)	Alter the IRB’s approval for the study 

 12.3 In the event research findings indicate that current and
past participants are at increased risk that was not anticipated at the time of the study design, the Principal Investigator, in accordance with both University IRB Policy and Procedures and the informed consent agreement, will immediately inform
research participants of risk alteration. 
 13. GENERAL 

13.1 Neither Party can assign its rights under this Agreement without the prior written consent of the other Party, which consent will not be unreasonably
withheld. Notwithstanding the foregoing, no such consent shall be needed for a assignment by any Sponsor Entity to another Sponsor Entity of part or all of the assigning Sponsor Entity’s interest. After a Party has received 

 
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  
 9 

 
a written request for consent to assign, the receiving Party will respond in writing within thirty (30) days. If the receiving Party does not respond in writing within thirty (30) days, that
Party’s silence will be deemed to mean that the receiving Party consents to the assignment. Any assignment made without the written or deemed consent of the non-assigning Party will be null and void. Subject to the approval of University, which
may not be unreasonably withheld, Sponsor is permitted to assign this Agreement in connection with a merger or a sale or transfer of substantially all of its assets; provided, however, that such assignee shall have expressly assumed all of the
obligations and liabilities of Sponsor under this Agreement, and provided, further that, University may assign its right to receive payments hereunder. 

13.2 This Agreement constitutes the entire and only agreement between the parties relating to the Research Program, and all prior negotiations,
representations, agreements and understandings are superseded hereby. No agreements altering or supplementing the terms hereof may be made except by means of a written document signed by the duly authorized representatives of University and Funding
Sponsor. Terms and conditions which may be set forth (front, reverse, attached or incorporated) in any purchase order issued by Sponsor in connection with this Agreement shall not apply, except for informational billing purposes; i.e., reference to
purchase order number, address for submission of invoices, or other invoicing items of a similar informational nature. 
 13.3 Any notice required by this
Agreement by Articles 7, 8 or 10 shall be given prepaid, first class, certified mail, return receipt requested, addressed in the case of University to: 

The University of Texas System, O.G.C. 

201 West 7th Street 
 Austin, Texas
78701 
 Attention: Intellectual Property Section 

Phone: (512) 499-4462 
 FAX:
(512) 499-4523 
 Vice President for Research 

The University of Texas at Austin 

P.O. Box 7996, Mail Code G1400 

Austin, Texas 78713 
 Attention:
Technology Licensing Specialist 
 Phone: (512) 471-2995 

FAX: (512) 475-6894 
  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

  
 10 

 or in the case of the Sponsor to: 

Aeglea Development Company, Inc. 

815-A Brazos St., #101 
 Austin TX
78701 
 Attn: David G. Lowe 

Phone: [phone] 
 FAX:
(866) 873-2149 
 E-Mail: [email] 
 or at
such other addresses as may be given from time to time in accordance with the terms of this notice provision. 
 Notices and other communications regarding
the day-to-day administration and operations of this Agreement shall be mailed (or otherwise delivered), addressed in the case of University to: 

The University of Texas at Austin 

Office of Industry Engagement 

North Office Building-A, Suite 5.2 

Post Office Box 7727, MC A9300 

Austin, Texas 78712-1736 

Attention: Bill Catlett, Director 

Phone: (512) 471-3866 
 FAX:
(512) 471-7839 
 E-mail: industry@austin.utexas.edu 

with a copy to: 
 Dr. George Georgiou 

The University of Texas at Austin 

Department of Chemical Engineering 

Austin, Texas 78712 
 Phone: [phone]

 E-Mail: gg@che.utexas.edu 
 or in the case of
Sponsor to: 
 Aeglea Development Company, Inc. 

815-A Brazos St., #101 
 Austin TX
78701 
 Attn: David G. Lowe 

Phone: [phone] 
 FAX:
(866) 873-2149 
 E-Mail: [email] 
  

 
 [***]Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect
to this information. 

  
 11 

 13.4 This Agreement shall be governed by, construed, and enforced in accordance with the internal laws of the
State of Texas. 
 13.5 Each Party acknowledges that this Agreement and the performance thereof are subject to compliance with any and all applicable United
States laws, regulations, or orders, including those that may relate to the export of technical data, and each Party agrees to comply with all such laws, regulations and orders, including, if applicable, all requirements of the International Traffic
in Arms Regulations and/or the Export Administration Act, as may be amended. Sponsor further agrees that if the export laws are applicable, it will not disclose or re-export any technical data under this Agreement to any countries for which the
United States government requires an export license or other supporting documentation at the time of export or transfer, unless Sponsor has obtained prior written authorization from the U.S. Office of Export Control or other authority responsible
for such matters. 
 13.6 If any provision contained in this Agreement is held invalid, unenforceable or contrary to laws then the validity of the remaining
provisions of this Agreement shall remain in full force. In such instance, Parties shall use their best efforts to replace the invalid provision(s) with legally valid provisions having an economic effect as close as possible to the original intent
of Parties. 
 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized representatives. 

 

									
	THE UNIVERSITY OF TEXAS AT AUSTIN				AEGLEA DEVELOPMENT COMPANY, INC.
			
	/s/ Ty Helpinstill				/s/ David G. Lowe
	By: Ty Helpinstill				By: David G Lowe
					
	Title:		Assoc Dir, Office of Industry Engagement				Title:		CEO
					
	Date:		19 December 2013				Date:		12/24/13

  
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  
 12 

									
	AERASE, INC.				AEMASE, INC.
			
	/s/ David G. Lowe				/s/ David G. Lowe
	By: David G Lowe				By: David G Lowe
					
	Title:		CEO				Title:		CEO
					
	Date:		12/24/13				Date:		12/24/13

  

									
	AECASE, INC.				AE4ASE, INC.
			
	/s/ David G. Lowe				/s/ David G. Lowe
	By: David G Lowe				By: David G Lowe
					
	Title:		CEO				Title:		CEO
					
	Date:		12/24/13				Date:		12/24/13

  

									
	AE5ASE, INC.				AE6ASE, INC.
			
	/s/ David G. Lowe				/s/ David G. Lowe
	By: David G Lowe				By: David G Lowe
					
	Title:		CEO				Title:		CEO
					
	Date:		12/24/13				Date:		12/24/13

  
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  
 13 

 ATTACHMENT A — RESEARCH PROGRAM 

Aeglea LLC will sponsor research in the laboratory of Professor George Georgiou, Depts of Chemical Engineering, Biomedical Engineering and
Molecular Biosciences on the engineering, optimization and initial animal validation of human enzyme therapeutics for the following purposes: 

Specific Aim 1. The systemic depletion of amino acids for cancer therapy, as elaborated below. 

Specific Aim 2. Enzyme replacement for the treatment of patients having inborn metabolic defects, primarily but not limited to diseases
stemming from mutations impacting physiological enzymatic function. 
 It is anticipated that during the 2013-2014 fiscal year, the work to
be carried out at the Georgiou lab will focus primarily, but not exclusively on Specific Aim 1. During this period the Georgiou lab will seek to focus on the engineering and optimization of the following enzymes: 

 

	 	1.1	[***] 

  

	 	1.2	[***] 

  

	 	1.3	[***] 

  

	 	1.4	[***] 

 Studies to be performed under 1.1-1.4 may include: 

 

	 	a)	Engineering enzymes having high catalytic proficiency (kcat/Km) and substrate specificity, as required for human therapeutic purposes. 

 

	 	b)	High thermodynamic stability in vitro and in physiological fluids, namely in human serum 

  

	 	c)	Formulation of the enzymes from 1.1-1.4 for prolonged circulation half-life by conjugation or polyethylene glycol or similar means. 

  

	 	d)	Development of lab scale processes for the preparative production of these enzymes at scale. 

  

	 	e)	In vitro studies to evaluate the effect of the engineered enzymes from 1.1-1.4 on cancer cell lines and, if available on primary tumor cells. 

 

	 	f)	Evaluation of the efficacy of the enzymes from 1.1-1.4 above in xenograft tumor mouse models, as applicable. 

  

	 	g)	Mechanistic studies as might be required to support Investigative New Drug applications (IND) to the FDA specifically addressing the impact of enzymes from 1.1-1.4 on cell cycle arrest, autophagy and apoptotic death of
cancer cells. 

  
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  
 14 

 ATTACHMENT B 

SPONSORED RESEARCH AGREEMENT UTA13-001113 

Identification of Background IP and Restrictions on its Use, Release, 

or Disclosure 
 University’s Principal
Investigator asserts that the following identifies the Background IP (BIP) developed by University researchers performing under the Research Program and restrictions that exist on the rights of the entity owning or controlling the BIP to use,
release, or disclose the BIP. 
 Controlled by George Georgiou and exclusively licensed by Sponsor: 

 

			
	“Arginase formulations and methods”
	Serial No. 13/380,776		United States
	Serial No. PCT/US2010/040205		International
	Serial No. 61/221,396		United States
	Serial No. 10800270.0 (Publication No. EP2449102)		European Patent Office
	Serial No. 12111085.9		Hong Kong
	Serial No. 2012-517824		Japan
	Serial No. 2,766,039		Canada
	“Engineered Enzymes with Methionine-Gamma-Lyase Enzymes and
Pharmacological Preparations Thereof”
	Serial No. 61/301,368		United States
	Serial No. 13/020,268		United States
	Serial No. PCT/US2011/023606		International
	Serial No. 2011212885•		Australia
	Serial No. 2,788,689		Canada
	Serial No. 201180013307.X		China
	Serial No. 11740355		European Patent Office
	Serial No. 2012-552084		Japan
	Serial No. 10-2012-7023176		Republic of Korea .
	“Compositions of Engineered Human Arginases and Methods for Treating
Cancer”
	Serial No. 12/610,685		United States
	Serial No. 61/110,218		United States
	Serial No. PCT/US2009/062969		International
	 Serial No. 09824219.1

(Publication No. EP2350273)
		European Patent Office
	Serial No. 12100429.7		Hong Kong
	Serial No. 2,742,497		Canada
	Serial No. 2011-534855 (Publication No. JP2012507301)		Japan

  
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  
 15 

			
	Background IP * and party owning or controlling that BIP		 Restrictions on BIP**
  

(If restrictions exist, describe nature of restrictions and third party that holds the rights thereto.) (If no restrictions exist, state
“none”)

		
	Owned by The University of Texas at Austin:		Exclusively licensed by Sponsor:
		
	 Engineering of L-Cysteine/L-Cystine degrading enzymes for therapeutic purposes.
		 PLA number PM1400601 (6337 GEO)
  

BIP: 61/871,727 (provisional patent application number)

		
	 Improvement on UTSB 741 “Engineered methionine gammal-lyase enzymes and pharmacological preparations thereof
		 PLA number PM4011501 (6314 GEO)
  

BIP: 61/871,768 (provisional patent application number)

 * “Background II” means any and all patents or patent applications for inventions, discoveries or
technology developed prior to the date hereof which necessarily would be infringed by the making, use or sale of a product the making, use or sale of which would also infringe a claim of a patent or patent application for any invention, discovery or
technology reasonably expected to result from the performance of the Research Program. If the BIP is applicable to multiple items, components, or processes identify both the BIP and each such item, component, or process. 

**Restrictions on BIP may include licenses granted by the owner of the BIP or industrial sponsorship arrangements that allow the sponsor
rights to review publications or to negotiate a license. Indicate whether development was funded either exclusively or partially by a government or non-government source, and list the source. Enter any reason that owner’s ability to grant
licenses in the BIP could be restricted. Identify basis of restriction (e.g., rights from a pre-existing agreement, rights in data generated under another contract, limited purpose rights under this or a prior contract, or specifically negotiated
licenses). 
  

			
	Printed Name:		George Georgiou
		
	Title:		Professor
		
	Signature		/s/ George Georgiou
		
	Date		 December 6, 2013

  
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  
 16 

 Amendment 1 

To Sponsored Research Agreement UTA13-001113 (“Agreement”) 

Betwee 
 The University of
Texas at Austin (“UT”) 
 And 

Aeglea Development Company, Inc., AERase, Inc., AEMase, Inc., AECase, Inc., AE4ase, Inc., 

AE5ase, Inc., and AE6ase, Inc. (each a “Sponsor Entity” and collectively, “Sponsor”) 

The purpose of this Amendment: 
 To extend
the period of performance and increase the limitation of funding to perform additional research. 
 This Sponsored Research Agreement
is modified by mutual agreement of the Parties 
 as follows: 

 

	1.	Attachment A, Statement of Work, is appended with the Statement of Work included with this Amendment 1 as Attachment A-1, attached hereto. 

 

	2.	Section 2.2 is hereby replaced with the following: “The Research Program shall be performed during the period from the Effective Date through and including January 15, 2016 (the “Research
Term”). Funding Sponsor shall have the option of extending the Research Program under mutually agreeable support terms. 

  

	3.	Section 3.2, first paragraph and payment schedule, are hereby replaced with the following: “As consideration for the performance by University of its obligations under this Agreement, Funding Sponsor will pay
the University an amount equal to its reasonable, documented expenditures and reasonable overhead (such overhead to not exceed the rate set forth in University’s indirect rate agreement with the U.S. Federal Government) in conducting the
Research Program subject to a maximum expenditure limitation of $761,252, an increase of $375,000 over the currently funded amount of $386,252, provided that in any and all events, the amounts charged by University shall not, without Funding
Sponsor’s prior written consent, exceed the amount of the maximum expenditure limitation. Funding Sponsor has paid University $386,252 as consideration for its performance under the Research Program as described in Attachment A. Payments under
the following Attachment A-1 shall be made as follows (subject to the possible later return of funds if uncommitted and unexpended, under Section 3.3): 

  

	 	a)	Upon execution of all parties to the Agreement: $93,750; 

  

	 	b)	$93,750 by March 31, 2015; and 

  

	 	c)	$93,750 by June 30, 2015 

  

	 	d)	$93,750 by Sept 30, 2015” 

  

			
	Effective Date of the Sponsored Research Agreement:		December 1, 2013
	Effective Date of Amendment:		January 15, 2015

  
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  

					
	Sponsor: Aeglea		PI: George Georgiou		SRA Amendment No. 1
	The University of Texas at Austin		Page 1 of 3		Agreement No. UTA13-001113

 All other terms and conditions of this Sponsored Research Agreement remain unchanged. 

 

									
	THE UNIVERSITY OF TEXAS AT AUSTIN				AEGLEA DEVELOPMENT COMPANY, INC.
			
	/s/ Ty Helpinstill				/s/ David G. Lowe
	By: Ty Helpinstill				By: David G Lowe
	Title:		Assoc Dir, Office of Industry Engagement				Title:		CEO
	Date:		28 October 2014				Date:		11/13/14

  

									
	AERASE, INC.				AEMASE, INC.
			
	/s/ David G. Lowe				/s/ David G. Lowe
	By: David G Lowe				By: David G Lowe
	Title:		CEO				Title:		CEO
	Date:		11/13/14				Date:		11/13/14

  

									
	AECASE, INC.				AE4ASE, INC.
			
	/s/ David G. Lowe				/s/ David G. Lowe
	By: David G Lowe				By: David G Lowe
	Title:		CEO				Title:		CEO
	Date:		11/13/14				Date:		11/13/14

  

									
	AE5ASE, INC.				AE6ASE, INC.
			
	/s/ David G. Lowe				/s/ David G. Lowe
	By: David G Lowe				By: David G Lowe
	Title:		CEO				Title:		CEO
	Date:		11/13/14				Date:		11/13/14

  
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  

					
	Sponsor: Aeglea		PI: George Georgiou		SRA Amendment No. 1
	The University of Texas at Austin		Page 2 of 3		Agreement No. UTA13-001113

 Attachment A-1, Statement of Work 

Aeglea LLC will sponsor research in the laboratory of Professor George Georgiou, Departments of Chemical Engineering, Biomedical Engineering
and Molecular Biosciences on the engineering, optimization and initial animal validation of human enzyme therapeutics for the following purposes: 

Specific Aim 1. The systemic depletion of amino acids for cancer therapy. 

Specific Aim 2. Enzyme replacement for the treatment of patients having inborn metabolic defects, primarily but not limited to diseases
stemming from mutations impacting physiological enzymatic function. 
 It is anticipated that during the 2014-2015 fiscal year most of the
work to be carried out at the Georgiou lab will focus primarily, but not exclusively on Specific Aim 1. During this period the Georgiou lab will seek to focus on the engineering and optimization of the following enzymes: 

 

	 	1.1.	[***] 

  

	 	1.2.	[***] 

  

	 	1.3.	[***] 

  

	 	1.4.	[***]: 

  

	 	a)	Engineering enzymes having high catalytic proficiency (kcat/Km) and substrate specificity, as required for human therapeutic purposes. 

 

	 	b)	High thermodynamic stability in vitro and in physiological fluids, namely in human serum 

  

	 	c)	Formulation of the enzymes from 1.1-1.4 for prolonged circulation half-life by conjugation or polyethylene glycol or similar means. 

  

	 	d)	Development of lab scale processes for the preparative production of these enzymes at scale. 

  

	 	e)	In vitro studies to evaluate the effect of the engineered enzymes from 1.1-1.4 on cancer cell lines and, if available on primary tumor cells. 

 

	 	f)	Evaluation of the efficacy of the enzymes from 1.1-1.4 above in xenograft tumor mouse models, as applicable. 

  

	 	g)	Mechanistic studies as might be required to support Investigative New Drug applications (IND) to the FDA specifically addressing the impact of enzymes from 1.1-1.4 on cell cycle arrest, autophagy and apoptotic death of
cancer cells. 

  
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

  

					
	Sponsor: Aeglea		PI: George Georgiou		SRA Amendment No. 1
	The University of Texas at Austin		Page 3 of 3		Agreement No. UTA13-001113

 Amendment 01 

To Sponsored Research Agreement UTA13-001113 (“Agreement”) 

This Amendment to the Sponsored Research Agreement (“Agreement”) is made between The University of Texas at Austin, Austin, Texas
(“University”), an institution of higher education created by the Constitution and law of the State of Texas under The University of Texas System (“System”) and Aeglea Development Company, Inc., AERase, Inc., AEMase, Inc.,
AECase, Inc., AE4ase, Inc., AE5ase, Inc., and AE6ase, Inc., all Delaware C corporations with their principal place of business at 815 A Brazos St., #101, Austin TX 78701 (each a “Sponsor Entity” and collectively, “Sponsor”).
Aeglea Development Company, Inc. may be referred to herein as the “Funding Sponsor” or “Sponsor Entity” as appropriate. 

The purpose of this Amendment: 
 Sponsor
and University desire to amend the terms of the Agreement to extend the performance period at no cost as set forth below. 
 This
Agreement is modified by mutual agreement of the Parties as follows: 
 1. Article 2. Research Program, paragraph 2.2 is hereby amended to read: 

The Research Program shall be performed during the period from the Effective Date through and including January 15, 2015. Funding Sponsor
shall have the option of extending the Research Program under mutually agreeable support terms. 
 All other terms and conditions of this
Agreement remain unchanged. 
 IN WITNESS WHEREOF, the parties have caused this Amendment to be executed by their duly authorized representatives. 

 

									
	THE UNIVERSITY OF TEXAS AT AUSTIN				AEGLEA DEVELOPMENT COMPANY, INC.
			
	/s/ Ty Helpinstill				/s/ David G. Lowe
	By: Ty Helpinstill				By: David G Lowe
	Title:		Assoc Dir, Office of Industry Engagement				Title:		CEO
	Date:		24 September 2014				Date:		9/23/14

  

									
	AERASE, INC.				AEMASE, INC.
			
	/s/ David G. Lowe				/s/ David G. Lowe
	By: David G Lowe				By: David G Lowe
	Title:		CEO				Title:		CEO
	Date:		9/23/14				Date:		9/23/14

  
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. 

									
	AECASE, INC.				AE4ASE, INC.
			
	/s/ David G. Lowe				/s/ David G. Lowe
	By: David G Lowe				By: David G Lowe
	Title:		CEO				Title:		CEO
	Date:		9/23/14				Date:		9/23/14

  

									
	AE5ASE, INC.				AE6ASE, INC.
			
	/s/ David G. Lowe				/s/ David G. Lowe
	By: David G Lowe				By: David G Lowe
	Title:		CEO				Title:		CEO
	Date:		9/23/14				Date:		9/23/14

  
  

[***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]